Rhode Island Chronicle

DelveInsight Business Research LLP

DelveInsight’s “Pancreatic Ductal Adenocarcinoma – Pipeline Insight, 2023,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Pancreatic Ductal Adenocarcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Pancreatic Ductal Adenocarcinoma Overview

Pancreatic ductal adenocarcinoma is one of the most lethal diseases, with an average 5-year survival rate of less than 10%. Unfortunately, most patients have unresectable, locally advanced, or metastatic disease at the time of diagnosis. PDAC development is associated with a poor prognosis due to its complicated and multifactorial nature. There is a lack of simple, early detection methods, and is typically diagnosed at a late stage because symptoms do not appear until the disease has progressed and metastasized to distinct sites. The major difficulties in treating pancreatic cancer lie at both the genetic and cellular levels. The extent of mutational changes in pancreatic tumors generates gene instability that appears to play an essential role in PDAC tumor growth and treatment resistance.

Key Companies Working in the Pancreatic Ductal Adenocarcinoma Market Includes

•   Cardiff Oncology

•   XOMA

•   Alphamab

•   Cantargia

•   RenovoRx

•   Syntrix Biosystems

•   Eucure Biopharma

•   Panbela Therapeutics

•   Jeil Pharmaceutical

And many others 

Pancreatic Ductal Adenocarcinoma Therapies Covered and Analyzed in the Report:

• Nadunolimab

• Zimberelimab

• Palbociclib

• Onvansertib

•  Leucovorin

• Fluorouracil

•  NIS793

• Gemcitabine

• Abemaciclib

And many others

Read more about the Key Companies and Emerging Therapies in the Pancreatic Ductal Adenocarcinoma Market 

Table of Contents

1. Key Insights 

2. Pancreatic Ductal Adenocarcinoma Introduction 

3. Executive Summary of Pancreatic Ductal Adenocarcinoma

4. Disease Background and Overview

5. Epidemiology and patient population

6. Pancreatic Ductal Adenocarcinoma Emerging Therapies

7. Pancreatic Ductal Adenocarcinoma Market Outlook

8. Market Access and Reimbursement of Therapies

9. Market Drivers 

10. Market Barriers 

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

Learn more about the detailed offering of the report @ Pancreatic Ductal Adenocarcinoma Market Outlook 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services